Who Generates More Revenue? Perrigo Company plc or Xencor, Inc.

Revenue Showdown: Perrigo vs. Xencor

In the dynamic world of pharmaceuticals and biotechnology, revenue generation is a key indicator of a company's market position and growth potential. Over the past decade, Perrigo Company plc has consistently outperformed Xencor, Inc. in terms of revenue. From 2014 to 2023, Perrigo's annual revenue averaged around $4.68 billion, dwarfing Xencor's average of approximately $109 million. This stark contrast highlights Perrigo's dominance, with revenues nearly 43 times greater than Xencor's.

A Decade of Growth

Perrigo's revenue peaked in 2016 at $5.28 billion, while Xencor's highest revenue was $275 million in 2021. Despite fluctuations, Perrigo maintained a steady revenue stream, showcasing its resilience and market strength. Meanwhile, Xencor's revenue growth, though modest, reflects its potential in the biotech sector. As the industry evolves, these companies' financial trajectories offer valuable insights into their strategic directions and market adaptability.